Dexrazoxane Hydrochloride

盐酸右雷佐生

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameDexrazoxane Hydrochloride
Drug Alias Name右雷佐生盐酸盐Dexrazoxanum右丙亚胺盐酸盐Dexrazoxane盐酸地拉佐生 +[18] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsCytoprotective adjuvantChemotherapy induced poisoningExtravasation of Diagnostic and Therapeutic Materials +[9] 
Global Approved IndicationsCytoprotective adjuvantChemotherapy induced poisoningCardiotoxicity
Approved Indications in ChinaCytoprotective adjuvant
Original Approved Country/TerritoryItaly
Original Approved Date1992/02/17
Country/TerritoryUnited StatesPolandNetherlands +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesClinigen Inc
China Registration ClassN/A

Develop Information

Active CompaniesCNX Therapeutics LtdIndiana University School Of MedicineUniversity of Arkansas +[5] 
Inactive CompaniesPfizer IncFudan UniversityThe University Of Texas At Austin +[4] 
Active IndicationsCytoprotective adjuvantExtravasation of Diagnostic and Therapeutic MaterialsMyocardial Infarction +[4] 
Inactive IndicationsChemotherapy induced poisoningCardiomyopathiesHeart Defects, Congenital +[5] 

Other Information

ATC CodeV03AF02
Related LinksWikipediaDrugBankKEGG